Reflow Medical Presents Positive 12-Month Results for Spur Stent System in CLTI Patients
Reflow Medical, Inc., a company specializing in medical devices for cardiovascular diseases, has announced the 12-month results of its DEEPER REVEAL clinical trial. The trial evaluated the Spur Peripheral Retrievable Stent System in patients with chronic limb-threatening ischemia (CLTI) and below-the-knee arterial disease. Conducted across 49 U.S. centers with 130 patients, the study showed promising outcomes. The Spur Stent System, which received FDA De Novo clearance in May 2025, demonstrated a primary patency rate of 78.0% and freedom from clinically driven target lesion revascularization of 83.1% in appropriately sized target vessels. The trial results were presented at the Society of Interventional Radiology 2026 Annual Scientific Meeting in Toronto. 
